Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
WALTHAM, Mass., April 01, 2016 -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on March 28, 2016, the compensation committee of the company's board of directors granted sixteen new non-executive employees options to purchase an aggregate of 171,600 shares of the company's common stock with a per share exercise price of $30.25, the closing trading price of the company’s common stock on the NASDAQ Global Market on the grant date. Each option vests 25% on the first anniversary of the employee’s hire date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term. The stock options were granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules for equity grants to induce the new employees to enter into employment with the company.
About Radius Health
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer. For more information, please visit www.radiuspharm.com.
Radius Health Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825 Media Contact: Lori Gorski Email: [email protected] Phone: 617-551-4096
